Business and Finance

HDA issues a report detailing recalls and returns

Alliance for Regenerative Medicine tries to rationalize how payers address economic value

FDA working group’s effort is part of a larger move to realign drug pricing policies

PBMs, wholesalers and insurers lose over $20 billion in stock value on day of announcement

Will a combination of better diagnosis resources and cost cutting lead to better patient outcomes?

Data are down for 2016-7, but still relatively high compared to prior years; UPDATED

Questions raised over how prescription dosages translate into bulk consumption; IQVIA ‘stand(s) behind our data methodologies’

Eagerly anticipated address avoids major policy changes while chipping away at well-recognized pricing disincentives

With new cellular and genetic therapies, the reimbursement process will need to evolve

Purchases totaled $19.3 billion, up 19% over 2016, say Drug Channels' Adam Fein

Move comes as drug pricing policies get heightened attention in Washington

Company celebrates its growth at annual industry event

While nominal spending was up 1.4%, actual net spending was only 0.6% greater than 2016

Projected growth rates for outsourced work range from 12 to 17%

So-called ‘off the shelf’ CAR-T treatments could change the field just as first products enter commercialization

Existing ‘pay for performance’ models do not scale up well yet

Forecast is for 3-6% CAGR through 2022

$67-billion Cigna bid, if permitted, would pull in the last large independent PBM

Financial analysis shows PBMs’ greater conversion of profits to earnings

Dohmen Life Sciences Services is joined to a trio of recent acquisitions

Rite Aid brand will be expanded to include Albertsons’ pharmacies

Merger of two giants in their respective fields has global implications

New software solutions and an updated Revenue Cloud for Pharma

Most proposed solutions are already in the works

Another attempt by payers to control their healthcare costs; possible broader implications